ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO797

Donor Derived Cell-Free DNA in Stable Dual Kidney Transplant Recipients

Session Information

Category: Transplantation

  • 2002 Transplantation: Clinical

Authors

  • Yadav, Kunal, The University of Toledo, Toledo, Ohio, United States
  • Kaur, Navchetan, Natera, Inc., Austin, Texas, United States
  • Barnes, David C., Natera, Inc., Austin, Texas, United States
  • Ahmed, Ebad, Natera, Inc., Austin, Texas, United States
  • Gauthier, Phil, Natera, Inc., Austin, Texas, United States
Background

Dual kidney transplants from deceased donors with limited renal function expand the donor pool to help circumvent the organ shortage. It is unclear whether the donor derived cell-free DNA (dd-cfDNA) fraction, a validated biomarker for the detection of allograft injury, has a different baseline in individuals with dual kidney transplants, compared to those with single kidney transplants. Here we evaluate the baseline dd-cfDNA in a cohort of stable dual kidney transplant recipients (DKTR).

Methods

dd-cfDNA testing was performed clinically with the ProsperaTM test (Natera, Inc.) on 117 plasma samples from 13 DKTR. dd-cfDNA fractions ≥ 1% were considered at high risk for rejection. Of these patients, 11/13 had functioning grafts, 2/13 patients had interstitial fibrosis and glomerulosclerosis on biopsy and 1/13 patient died during the study. A randomly selected clinical cohort consisting primarily of stable single kidney transplant recipients was chosen for comparison.

Results


The median time from transplant to sample collection was 6.4 months (IQR: 2.8-10.6 months). The median dd-cfDNA fraction in DKTR was 0.25% (IQR: 0.14%-0.39%) as compared to 0.23% (IQR: 0.12%-0.45%) from a clinical cohort of 5067 samples. However, in the initial three months post transplant median dd-cfDNA fraction was significantly higher in the DKTR cohort 0.46% (IQR: 0.28%-0.89%) compared to clinical samples 0.30% (IQR: 0.16%-0.54%) (p=0.002). The median dd-cfDNA was similar in organs with kidney donor profile index ≥ 85% vs. < 85%. Locally weighted scatterplot smoothing shows similar DKTR and clinical sample dd-cfDNA fraction trends, plotted against time since transplant, in Figure 1.

Conclusion

This preliminary analysis demonstrated that the baseline dd-cfDNA fractions in dual kidney transplants is comparable to that of single kidney transplants from standard criteria donors. Furthermore, the quality of the donor kidneys (KDPI) does not appear to affect baseline dd-cfDNA fractions. This study is limited due to the small cohort size. Future studies will be needed to validate these findings.